Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.
Type:
Grant
Filed:
May 17, 2011
Date of Patent:
January 6, 2015
Assignee:
Cebix, Inc.
Inventors:
Sheri Barrack, James Callaway, Michelle Mazzoni
Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise modified C-peptide derivatives which exhibit superior pharmacokinetic and biological activity in vivo.
Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.
Type:
Application
Filed:
May 4, 2012
Publication date:
August 30, 2012
Applicant:
CEBIX, INC.
Inventors:
Sheri Barrack, James Callaway, Michelle Mazzoni
Abstract: The present invention relates to modified forms of C-peptide, and methods for their use. In one aspect, the modified forms of C-peptide comprise PEGylated C-peptide derivatives comprising at least one PEG group attached to the N-terminus, which exhibit superior pharmacokinetic and biological activity in vivo.
Type:
Application
Filed:
May 17, 2011
Publication date:
July 12, 2012
Applicant:
CEBIX, INC.
Inventors:
Sheri Barrack, James Callaway, Michelle Mazzoni
Abstract: The present invention relates to the development of improved methods for treating erectile dysfunction associated with diabetes. Significantly, such dosing regimens can be combined with established methods for treating sexual dysfunction, including PDE5 inhibitors such as those sold under the trademark VIAGRA® to provide for significantly improved efficacy compared to the PDE5 inhibitor alone.
Abstract: Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits, can also maintain good glycemic control, and avoid excessive weight gain that may otherwise be associated with excessive insulin administration or caloric intake during C-peptide therapy.
Type:
Grant
Filed:
June 8, 2010
Date of Patent:
December 21, 2010
Assignee:
Cebix Inc.
Inventors:
John Wahren, Karin Ekberg, James Callaway
© 2025 Justia
